Dare Bioscience DARE
NASDAQ DARE
$0.84 -0.01 (-1.18%)
At close: Oct 2, 2026 · 4:00 PM EDT

Dare Bioscience (DARE) Asset Writedowns and Impairment (2017 - 2018)

Updated

Dare Bioscience (DARE) reported Asset Writedowns and Impairment of $5.19 million for FY2018, down 30.8% from $7.5 million in FY2017.

Analysis

Dare Bioscience (DARE) Asset Writedowns and Impairment (2017 - 2018) Analysis & Trends

  • According to Business Quant data, Asset Writedowns and Impairment came in at $7.5 million in FY2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Dare Bioscience 12.74 Mn -52.72 Mn -132,343.00
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2018 5.20 Mn
Mar 31, 2017 102,000.00
API Access

Dare Bioscience Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=DARE&period=max&api_key=YOUR_API_KEY